NVAX Novavax Inc.

13.05
+0.31  (+2%)
Previous Close 12.74
Open 12.65
Price To Book -3.62
Market Cap 672,451,375
Shares 51,528,841
Volume 8,235,058
Short Ratio
Av. Daily Volume 9,657,988
Stock charts supplied by TradingView

NewsSee all news

  1. Novavax' NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

    Trial also achieves statistical significance in key secondary endpointsNovavax to submit a U.S. BLA under FDA's accelerated approval pathwayCompany to host investor conference call today at 8:30 a.m. EDT

  2. Novavax Reports Fourth Quarter and Full Year 2019 Financial Results

    NanoFlu top-line data from Phase 3 clinical trial expected by the end of this monthNovavax awarded CEPI funding to support COVID-19 vaccine programCOVID-19 Phase 1 clinical trial expected to initiate in late spring of

  3. Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

    Novavax' proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford UniversityPhase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M

  4. Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease

    GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will collaborate with

  5. Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

    CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trialsPhase 1 clinical trial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data met primary endpoints - March 24, 2020.
NanoFlu vaccine
Influenza
Phase 3 released September 15, 2016 did not demonstrate efficacy.
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 top-line data released March 28, 2019 - primary endpoint not met. Noted June 10, 2019 that a further Phase 3 trial is required.
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Phase 1 trial to commence by the end of spring 2020.
Matrix-M
Coronavirus COVID-19 vaccine
Phase 2b data due 2Q 2020.
Matrix-M
Malaria vaccine

Latest News

  1. Novavax' NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

    Trial also achieves statistical significance in key secondary endpointsNovavax to submit a U.S. BLA under FDA's accelerated approval pathwayCompany to host investor conference call today at 8:30 a.m. EDT

  2. Novavax Reports Fourth Quarter and Full Year 2019 Financial Results

    NanoFlu top-line data from Phase 3 clinical trial expected by the end of this monthNovavax awarded CEPI funding to support COVID-19 vaccine programCOVID-19 Phase 1 clinical trial expected to initiate in late spring of

  3. Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

    Novavax' proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford UniversityPhase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M

  4. Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease

    GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will collaborate with

  5. Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

    CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trialsPhase 1 clinical trial

  6. Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020

    GAITHERSBURG, Md., March 05, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report

  7. Novavax Advances Development of Novel COVID-19 Vaccine

    Vaccine candidate derived from coronavirus spike (S) proteinMatrix-M™ adjuvant expected to boost immune responsesPhase 1 clinical trial planned for late spring GAITHERSBURG, Md., Feb. 26, 2020 (GLOBE NEWSWIRE) --

  8. Novavax' Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity

    GAITHERSBURG, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a publication in

  9. Novavax Granted Fast Track Designation for NanoFlu in Older Adults

    GAITHERSBURG, Md., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S.

  10. Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference

    GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will

  11. Novavax Reports Third Quarter 2019 Financial Results

    NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., Nov. 07, 2019 (GLOBE

  12. Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019

    GAITHERSBURG, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report

  13. Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults

    First participants enrolled in pivotal Phase 3 clinical trial of NanoFlu Top-line clinical data expected in the first quarter of 2020 Phase 3 results expected to support a future BLA and licensure of NanoFlu using the

  14. Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    GAITHERSBURG, Md., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C.

  15. Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    GAITHERSBURG, Md., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C.